Objective To systematically review the efficacy of vortioxetine in the treatment of depressive disorder. Methods We conducted a Meta-analysis comparing vortioxetine versus placebo in the treatment of depressive disorder. The randomized controlled trials （RCT） were searched up to March 2019 in PubMed， Embase， Cochrane Library， CNKI and Wanfang database. Results A total of 13 RCTs involving 6 261 patients with depressive disorder were identified. The response rate with vortioxetine was significantly higher for 5 mg （RR=1.31，95%CI=1.15-1.49，P ＜ 0.01）， 10 mg （RR=1.39，95%CI=1.26-1.54，P ＜ 0.01）， 20 mg doses （RR=1.51，95%CI=1.20-1.90，P＜ 0.01） compared to placebo. Remission rates were significantly higher for the 10 mg group （RR=1.37，95%CI=1.19-1.57，P＜ 0.01） and the 20 mg group （RR=1.55，95%CI： 1.15-2.10，P ＜ 0.01） compared to placebo. Conclusions Vortioxetine was significantly more effective than placebo for acute treatment of depressive disorder. Nonetheless， more clinical studies of longer observation duration are needed to validate our result.